98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bpa.2020.11.002 | DOI Listing |
Int J Surg
September 2025
Experimental Tumorpathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Drug Des Devel Ther
September 2025
Department of Anesthesiology, Peking University People's Hospital, Beijing, People's Republic of China.
Background: The dopamine D2/D3 antagonist amisulpride has demonstrated its superiority and efficacy in prophylaxis of postoperative nausea and vomiting (PONV). Given the branded intravenous amisulpride (Barhemsys) has not been approved in China, there is unmet clinical need for amisulpride. Our primary objective was to ascertain the efficacy and safety of the generic intravenous amisulpride (QLG2069) in the prophylaxis of PONV.
View Article and Find Full Text PDFSurg Endosc
September 2025
Metabolic and Obesity Surgery Unit, ARNAS G. Brotzu, Cagliari, Italy.
Reg Anesth Pain Med
September 2025
Department of Anesthesiology, Critical Care & Pain Management, Hospital for Special Surgery, New York, New York, USA
Reg Anesth Pain Med
September 2025
Department of Anesthesiology and Reanimation, Ministry of Health Ankara Bilkent City Hospital, Ankara, Turkey.